ERBB2 and gastroesophageal junction adenocarcinoma: FDA-approved ADCs include trastuzumab deruxtecan (Enhertu), targeting HER2 for HER2-positive gastric and gastroesophageal junction adenocarcinoma; its DESTINY-Gastric01 trial showed significant efficacy [301, 302].